Biotech news for Wednesday, June 3, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
ModernLife Rezolute ( RZLT ) shares traded higher on Tuesday after the company announced an update from a late-stage trial for its lead candidate, ersodetug in tumor hyperinsulinism, a rare disease characterized by low blood sugar levels. Citing eight patients…
Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies , including among the market's most expensive names based on valuation grades. Seeking Alpha's valuation grade compare…
Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $2B and $10B highlights several mid-cap companies, including Apogee Therapeutics ( APGE ), Belite Bio ( BLTE ), and Bruker Corporation ( BRKR ), among the market's most ex…
Celcuity ( CELC ) shares dropped over 20% in the morning trading on Tuesday after the oncology-focused biotech posted detailed data from a Phase 3 trial testing its lead candidate, gedatolisib, in breast cancer. The Phase 3 VIKTORIA-1 trial, designed to evalua…
Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations above $10 billion highlights several large-cap companies, including Agilent Technologies ( A ), Danaher Corporation ( DHR ), and GE HealthCare Technologies ( GEHC ), among the mar…
UroGen Pharma ( URGN ) announced on Tuesday that it reached a settlement and license agreement with Teva Pharmaceuticals ( TEVA ) to resolve a patent dispute over its cancer therapy Jelmyto. The dispute arose after the Israeli drugmaker sought to market a gene…
narvikk Deal-making between U.S. and Chinese biopharma companies continued this week, with the California-based biotech Travere Therapeutics ( TVTX ) announcing a licensing agreement worth up to $1.1B with China's Everest Medicines on Tuesday. Under the exclus…
anilakkus Praxis Precision Medicines ( PRAX ) traded lower in extended trading after announcing that its Phase 2/3 POWER1 study evaluating its experimental therapy, vormatrigine, in focal onset seizures failed to meet the primary endpoint. The study for adults…
eternalcreative The European Commission has approved AbbVie's ( ABBV ) Aquipta (atogepant) as a treatment for migraine, with or without aura. Approval was based on results from the phase 3 ECLIPSE trial that showed those on atogepant had statistically signific…
Ashi Sae Yang Abivax ( ABVX ) plunged in premarket trading on Tuesday despite announcing positive Phase 3 maintenance trial results for its ulcerative colitis drug, obefazimod. The medicine met its endpoints of demonstrating a clinically meaningful efficacy an…
Summit Therapeutics ( SMMT ) closed Monday down ~10% despite releasing positive late-stage data on Sunday on ivonescimab as a first-line treatment for non-small cell lung cancer. Results from the HARMONi-6 study indicated that ivonescimab plus c hemotherapy cu…
aprott Moderna ( MRNA ) and Merck ( MRK ) said that the experimental cancer vaccine intismeran autogene plus Keytruda (pembrolizumab) led to a 49% decline in the risk of recurrence or death, and a 50% reduction in the risk of distant metastasis, compared to Ke…
Exicure ( XCUR ) received a Nasdaq non-compliance notice on May 28, 2026. The notice relates to the company’s failure to timely file its Q1 2026 report. The filing delay was primarily caused by changes in financial reporting personnel and related filing proced…
BlackRock Intermediate Muni Income Bond ETF ( INMU ) - $0.0666 . 30-Day SEC Yield of 3.38% as of May. 28. Payable Jun 04; for shareholders of record Jun 01; ex-div Jun 01. More on ImmunityBio ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar…
Vladimir Zakharov A screen of U.S. stocks with market capitalizations between $300M to $2B highlights AdaptHealth ( AHCO ), Community Health Systems ( CYH ), and Rigel Pharmaceuticals ( RIGL ) among the market's most attractively valued companies relative to t…